enzastaurin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mantle-Cell Lymphoma
Conditions
Mantle-Cell Lymphoma
Trial Timeline
Mar 1, 2004 → May 1, 2008
NCT ID
NCT00088205About enzastaurin
enzastaurin is a phase 2 stage product being developed by Eli Lilly for Mantle-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00088205. Target conditions include Mantle-Cell Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01432951 | Phase 1 | Completed |
| NCT00744991 | Phase 2 | Completed |
| NCT00718419 | Phase 2 | Completed |
| NCT00542919 | Phase 2 | Completed |
| NCT00475644 | Phase 2 | Completed |
| NCT00452257 | Phase 1 | Completed |
| NCT00420381 | Phase 2 | Completed |
| NCT00428714 | Phase 2 | Completed |
| NCT00309140 | Phase 2 | Completed |
| NCT00088205 | Phase 2 | Completed |
| NCT00190723 | Phase 2 | Completed |
Competing Products
9 competing products in Mantle-Cell Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pirtobrutinib + Ibrutinib + Acalabrutinib + Zanubrutinib | Eli Lilly | Phase 3 | 77 |
| Venetoclax | AbbVie | Phase 2 | 52 |
| ABT-199 and Ibrutinib Combination | AbbVie | Phase 1 | 33 |
| Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapy | AstraZeneca | Phase 2 | 52 |
| SCH 727965 + Bortezomib + Alemtuzumab | Merck | Phase 2 | 52 |
| Obinutuzumab + Glofitamab + Venetoclax Oral Product + Zanubrutinib Oral Capsule | Roche | Phase 2 | 52 |
| PD-0332991 | Pfizer | Phase 1 | 32 |
| Copanlisib (BAY80-6946) | Bayer | Phase 2 | 49 |
| Yttrium-ibritumomab (Zevalin) + Rituximab | Biogen | Phase 2 | 49 |